NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/30/2022
Back to search
Official data from USPTO
ZIMED
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
25
Latest update
08/30/2022
Trademark type
Word
Nice classes
5, 10
Filing date
05/19/2021
Registration date
08/30/2022
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/30/2022
Last transaction
08/30/2022
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
4
Owner type
99
Owner location
London, GB
Examiner
JANSON, ANDREW KYLE
Law office
L50
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Medicom Healthcare Limited
Representatives
Luna M. Samman ArentFox Schiff LLP
Technical classification
Nice Classes
Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of glaucoma; Ophthalmic preparations for the treatment of glaucoma; Eye drops for the treatment of glaucoma; Eye ointments for medical use in the treatment of glaucoma; Medicated pre-moistened eye wipes for medical use for the treatment of glaucoma; Eye patches for medical purposes for the treatment of glaucoma; Medicated eye-washes for the treatment of glaucoma; Tissues impregnated with pharmaceutical lotions for the treatment of glaucoma; Thermal eye compresses for the treatment of glaucoma; Eye baths being medicated eye washes for the treatment of glaucoma; Eye gels for medical and therapeutic use for the treatment of glaucoma; Eye pads for surgical use for the treatment of glaucoma
Class 10
Pharmaceutical apparatus relating to eye care for the treatment of glaucomaeye droppers for administering pharmaceutical preparations to the eye; Eye testing apparatus for the treatment of glaucoma; Ophthalmoscopes for the treatment of glaucoma; Optometric instruments for the treatment of glaucoma; Artificial lenses for implantation in the eye for the treatment of glaucoma; eye droppers for the treatment of glaucoma
Publications
History of USPTO decisions and trademark events.
25 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
08/30/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/14/2022
PUBO
PUBLISHED FOR OPPOSITION
06/14/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/25/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/12/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
05/12/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/12/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
05/12/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/12/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/21/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/21/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
04/21/2022
ALIE
ASSIGNED TO LIE
04/18/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/13/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/03/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
03/03/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/03/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/03/2022
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/26/2022
GNRT
NON-FINAL ACTION E-MAILED
01/26/2022
CNRT
NON-FINAL ACTION WRITTEN
01/26/2022
DOCK
ASSIGNED TO EXAMINER
01/26/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/17/2021
NWAP
NEW APPLICATION ENTERED
05/22/2021
Continuous trademark protection
Get notified about every new filing that threatens ZIMED or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.